Metastatic Squamous Neck Cancer with Occult Primary Treatment (PDQ®): Treatment - Patient Information [NCI] - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support
Intraocular (Uveal) Melanoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Medium and Large Choroidal Melanoma
Eye-sparing radiation therapy, either by plaque brachytherapy or external beam, is the preferred option for most patients with medium-sized choroidal melanoma. Enucleation remains the standard therapy for large, choroidal melanomas and melanomas that cause severe glaucoma or invade the optic nerve. Standard treatment options:Tumor growth pattern is a factor in the therapeutic decision. If there is a diffuse melanoma or if there is extraocular extension, enucleation should be considered, but radiation therapy can be employed for less extensive disease. Medium-sized choroidal melanomasPlaque radiation therapy.[1,2,3,4]External-beam, charged-particle radiation therapy: This approach is offered at specialized referral centers. It requires careful patient cooperation, with voluntary fixation of gaze.[5,6,7]Local eye-wall resection.[8,9]Combined therapy, with ablative laser coagulation or transpupillary thermotherapy to supplement plaque treatment.[10,11]Enucleation. This approach is
Genetics of Skin Cancer (PDQ®): Genetics - Health Professional Information [NCI] - Introduction
Many of the medical and scientific terms used in this summary are found in the NCI Dictionary of Genetics Terms. When a linked term is clicked,the definition will appear in a separate window. Many of the genes described in this summary are found in the Online Mendelian Inheritance in Man (OMIM) database. When OMIM appears after a gene name or the name of a condition,click on OMIM for a link ...
Skin Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options for Nonmelanoma Skin Cancer
A link to a list of current clinical trials is included for each treatment section. For some types or stages of cancer, there may not be any trials listed. Check with your doctor for clinical trials that are not listed here but may be right for you.Basal Cell CarcinomaTreatment of basal cell carcinoma may include the following:Simple excision.Mohs micrographic surgery.Radiation therapy.Electrodesiccation and curettage.Cryosurgery.Photodynamic therapy.Topical chemotherapy.Topical biologic therapy with imiquimod.Laser surgery.Treatment of recurrent basal cell carcinoma is usually Mohs micrographic surgery.Treatment of basal cell carcinoma that is metastatic or cannot be treated with local therapy is usually chemotherapy or a clinical trial of a new treatment.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with basal cell carcinoma of the skin. For more specific results, refine the search by using other search features, such as the
Skin Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - What is prevention?
Cancerprevention is action taken to lower the chance of getting cancer. By preventing cancer,the number of new cases of cancer in a group or population is lowered. Hopefully,this will lower the number of deaths caused by cancer. To prevent new cancers from starting,scientists look at risk factors and protective factors. Anything that increases your chance of developing cancer is called a ...
Skin Cancer Screening (PDQ®): Screening - Patient Information [NCI] - nci_ncicdr0000258037-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Skin Cancer Screening
Genetics of Skin Cancer (PDQ®): Genetics - Health Professional Information [NCI] - Rare Skin Cancer Syndromes
Brooke-Spiegler Syndrome, Multiple Familial Trichoepithelioma, and Familial CylindromatosisBrooke-Spiegler Syndrome (BSS), familial cylindromatosis, and multiple familial trichoepithelioma (MFT) are all autosomal dominant syndromes with overlapping clinical characteristics with allelic variance. Features of BSS include multiple skin appendage tumors such as cylindromas (tumors arising in the hair follicle stem cells), trichoepitheliomas (tumors arising in the hair follicle), and spiradenomas (benign tumors arising in the sweat gland). MFT is characterized by nonmalignant skin tumors, primarily trichoepitheliomas, and familial cylindromatosis manifests predominantly as cutaneous cylindromas. Onset of tumors for these syndromes is typically in late childhood or early adolescence, suggesting a hormonal influence. There is some evidence of greater severity in females than in males. UV radiation appears to be a major initiating factor for cylindromas. Typical tumor sites for
Skin Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - About This PDQ Summary
Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about skin cancer screening. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Screening and Prevention Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a consensus process in which
Intraocular (Uveal) Melanoma Treatment (PDQ®): Treatment - Patient Information [NCI] - General Information About Intraocular (Uveal) Melanoma
Intraocular melanoma is a disease in which malignant (cancer) cells form in the tissues of the eye.Intraocular melanoma begins in the middle of three layers of the wall of the eye. The outer layer includes the white sclera (the white of the eye) and the clear cornea at the front of the eye. The inner layer has a lining of nerve tissue, called the retina, which senses light and sends images along the optic nerve to the brain.The middle layer, where intraocular melanoma forms, is called the uvea or uveal tract, and has three main parts:IrisThe iris is the colored area at the front of the eye (the eye color). It can be seen through the clear cornea. The pupil is in the center of the iris and it changes size to let more or less light into the eye. Intraocular melanoma of the iris is usually a small tumor that grows slowly and rarely spreads to other parts of the body.Ciliary bodyThe ciliary body is a ring of tissue with muscle fibers that change the size of the pupil and the shape of the
Genetics of Skin Cancer (PDQ®): Genetics - Health Professional Information [NCI] - Squamous Cell Carcinoma
IntroductionSquamous cell carcinoma (SCC) is the second most common type of skin cancer and accounts for approximately 20% of cutaneous malignancies. Although most cancer registries do not include information on the incidence of nonmelanoma skin cancer, annual incidence estimates range from 1 million to 3.5 million cases in the United States.[1,2] Mortality is rare from this cancer; however, the morbidity and costs associated with its treatment are considerable.Risk Factors for Squamous Cell CarcinomaSun exposureSun exposure is the major known environmental factor associated with the development of skin cancer of all types; however, different patterns of sun exposure are associated with each major type of skin cancer. (Refer to the Sun exposure section in the Basal Cell Carcinoma section of this summary for more information.) This section focuses on sun exposure and increased risk of cutaneous SCC. Unlike basal cell carcinoma (BCC), SCC is